Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Vor Bio (Nasdaq: VOR) will present and host one-on-one investor meetings at the 44th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Bio (Nasdaq: VOR) will present and host one-on-one investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for Tuesday, January 13, 2026, 10:30 AM–11:10 AM PT at The Westin St. Francis, Georgian Room. A live webcast and archived replay will be available on the company website at https://ir.vorbio.com/events-presentations/. The company is clinical-stage and focuses on autoimmune disease treatments.
Details
News Market Reaction – VOR
On Jan 6, the day this news came out, VOR closed 10.30% above the previous close.
Data tracked by StockTitan Argus for the Jan 6 session.
Key Figures
- Conference date
- January 13, 2026
- Scheduled J.P. Morgan Healthcare Conference presentation
- Presentation time
- 10:30am–11:10am PT
- Vor Bio’s conference session window
- Current price
- $10.58
- Price before this conference news
- 52-week range
- $2.622–$65.80
- 52-week low and high prior to article
Historical Context
-
New investor-affiliated directors join board following prior PIPE financing.
-
Announced $150M private placement to fund telitacicept Phase 3 programs.
-
Q3 2025 results with positive telitacicept data and large non-cash warrant loss.
-
Pricing of $100M underwritten stock offering at $10.00 per share.
-
Proposed $100M equity offering using effective shelf registration.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
autoimmune diseases medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
Presentation: Tuesday, January 13, 2026 at 10:30am – 11:10 am PT
Location: The Westin St. Francis, Georgian Room
A live webcast and archived replay of the presentation will be available on the Company’s website at: https://ir.vorbio.com/events-presentations/
About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.
Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com
Sarah Spencer
investors@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.